PARTENAR-IA, a funding initiative to support public-private AI-based research projects !
DEADLINE: OCTOBER 15th, 2019
Montreal, August 20th, 2019 – The PARTENAR-IA initiative aims to accelerate the design and development of Artificial Intelligence (AI) technologies applicable in the biopharmaceutical sector by participating in the funding of collaborative research projects carried out in a Quebec public research institution. The grant can reach $500,000 to cover up to 40% of eligible R&D expenditures.
Collaborative projects funded under PARTENAR-IA present the following main characteristics:
- Research conducted in at least one public research institution in Quebec;
- Participation of one or more companies (depending on the technology readiness level), one of which carrying out production or R&D activities in Quebec. A cash contribution representing at least 20% of the eligible expenses is expected from the industrial partners;
- The remaining 40% of co-funding can come from private or government sources (other than MEI), including NSERC Alliance Grants.
Note that it is possible for CQDM to identify sources of co-funding to complete the financial arrangement of projects submitted under the PARTENAR-IA initiative. Interested researchers and entrepreneurs are invited to contact Marc Thibault (email@example.com) or Véronique Dugas (firstname.lastname@example.org) for further details on the application process as well as applicable co-funding opportunities. All information regarding the PARTENAR-IA call for projects is also available on the CQDM web page.
CQDM is a biopharma-based research consortium created in 2008 with the mission to fund the development of innovative technologies to accelerate the drug discovery and development. Its business model is based on a collaborative approach bringing together world-leading pharmaceutical organizations, Canadian biotech companies as well as the Canadian and Quebec governments who share the costs of the research. CQDM uses this leverage to reduce the risks inherent to early-stage biopharmaceutical research. In doing so, CQDM bridges the funding gap needed to drive innovation across the academic and private sectors, especially where early-stage research is concerned. Over the last 10 years, CQDM has benefited from the contribution of 13 industrial members: that includes Merck, Pfizer, AstraZeneca as founding members as well as Boehringer Ingelheim, Eli Lilly Canada, GlaxoSmithKline, Janssen, Novartis Pharma Canada, Roche, Sanofi Canada, Servier, Takeda and now Amgen. CQDM also received contributions from Quebec’s Ministry of Economy and Innovation (MEI) and from the Government of Canada under the Business-Led Networks of Centres of Excellence Program (BL-NCE). Since 2008, CQDM has supported the development of 64 outstanding innovative technologies totaling $68 M in funding. These R&D projects carried out by 1,200 scientists from 69 different research institutions (38 public and 31 private) across Canada, have generated numerous economic benefits for all the stakeholders of the life science ecosystem. For more information: http://www.cqdm.org/en
For additional information, please contact:
Véronique Dugas, Ph.D., MBA
Director, Fonds d’accélération des collaborations en santé
Marc Thibault, Ph.D.
Director of Business Development